Madrigal Pharmaceuticals, Inc. (MDGL) News
Track canonical SquawkNews coverage tagged to MDGL, Madrigal Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 19 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Madrigal Pharmaceuticals Price Target Announced at $704.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 12:51 PM UTC
L
Madrigal Pharmaceuticals Price Target Announced at $725.00/Share by Citigroup
Ratings actions from Benzinga: GMT) Madrigal Pharmaceuticals Initiated at Buy by CitigroupRatings actions from Benzinga
NEWS | Sep 23, 2026, 03:13 PM UTC
L
MDGL - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
MDGL - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 16, 2026, 08:05 PM UTC
M
MDGL reports Q2 sales of $364 million
MDGL said Q2 sales reached $364 million. The company also reported over 50,000 patients treated and described market uptake alongside a pipeline advancing.
EARNINGS | Sep 10, 2026, 07:03 PM UTC
L
Madrigal Pharmaceuticals to participate in 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals says it will take part in the 2026 Cantor Global Healthcare Conference on Thursday, Sept. 10, 2026 at 1:00 P.M. EDT. The presentation will be webcast live.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
MDGL to participate in 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals will participate in the 2026 Cantor Global Healthcare Conference.
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
Madrigal Pharmaceuticals grants inducement awards under Nasdaq Rule 5635(c)(4)
Madrigal Pharmaceuticals (MDGL) announces grants of inducement awards under Nasdaq Listing Rule 5635(c)(4).
REGULATION | Aug 20, 2026, 08:05 PM UTC
L
MDGL Appoints John C. Reed to Board
MDGL appoints John C. Reed, M.D., Ph.D., to its Board of Directors
MNA | Aug 12, 2026, 12:00 PM UTC
H
MDGL upgraded to Outperform at Wolfe
MDGL upgraded to Outperform with $605 price target
EQUITY | Aug 04, 2026, 09:44 AM UTC
H
Barclays Raises MDGL PT to $962
Barclays raises price target for MDGL
EQUITY | Aug 03, 2026, 09:59 AM UTC
L
MDGL Seen As Buying Opportunity
MDGL shares seen as buying opportunity
EARNINGS | Jul 31, 2026, 01:01 PM UTC
H
Madrigal Q2 Revenue Surges 71%
Madrigal revenue surges 71% year-over-year
EQUITY | Jul 30, 2026, 12:37 PM UTC
L
MDGL Madrigal Pharmaceuticals RESULTS: Q2, Q2 product REV $364.252M, Q2 Net Income $-57.939M, Q2 operating expenses $420.56M, Q2 Operating I
MDGL Madrigal Pharmaceuticals RESULTS: Q2, Q2 product REV $364.252M, Q2 Net Income $-57.939M, Q2 operating expenses $420.56M, Q2 Operating Income $-56.308M, Q2 EPS $-1.99
EARNINGS | Jul 30, 2026, 11:04 AM UTC
L
MDGL - Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
MDGL - Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
MDGL Initiated Overweight W/$685.00 PT at Wells Fargo
MDGL Initiated Overweight W/$685.00 PT at Wells Fargo
EQUITY | Jul 27, 2026, 12:08 PM UTC
L
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: O
Top Initiations: BSP DFTX GHRS HELP MDGL: OVERWEIGHT @ WFC CMPS: EQUAL WEIGHT @ WFC CIFR HIVE PMN WULF: BUY @ Chardan BWXT CDRE LIME RYTM: OVERWEIGHT @ JPM CLH ITG: BUY @ BAC ARLO WSM: OVERWEIGHT @ Piper ADUR: BUY @ ROTH
EQUITY | Jul 27, 2026, 11:09 AM UTC
L
MDGL initiated with an Overweight at WFC w/ $685 PT
MDGL initiated with an Overweight at WFC w/ $685 PT
EQUITY | Jul 27, 2026, 09:50 AM UTC
L
Reported Earlier, Ribo And Madrigal Achieve First Candidate Drug Nomination Milestone Within Their siRNA Partnership For Liver Disease
Reported Earlier, Ribo And Madrigal Achieve First Candidate Drug Nomination Milestone Within Their siRNA Partnership For Liver Disease
EQUITY | Jul 02, 2026, 06:54 AM UTC